Risk Factors for Cryptococcal Meningitis Recurrence in Human Immunodeficiency Virus (HIV)-Infected Patients in a Large Chinese Acquired Immune Deficiency Syndrome (AIDS) Treatment Center

15 December 2021: Clinical Research

Yue Zhou ^1AEF , Feng Li ^1BCD , Rui Li ^1BCD , Yuan Peng ^1CD , Mei He ^1CD , Fengjun Sun ^2ADEF* , Ming Yang ^12AEFG*

DOI: 10.12659/MSM.933688

Med Sci Monit 2021; 27:e933688

Table 2 Univariate analysis of risk factors for recurrence in cryptococcal meningitis patients.

Risk factor	OR	95% CI	P
Age	1.021	0.989–1.054	0.194
Sex	1.605	0.510–5.051	0.419
Diabetes	–	–	0.999
Malignant tumor	1.074	0.385–3.002	0.891
Autoimmune diseases	0.266	0.028–2.514	0.248
Cryptococcal pneumonia	2.420	0.868–6.748	0.091
Infection in other areas	0.525	0.134–2.058	0.355
Kidney disease	2.400	0.207–27.781	0.483
Liver disease	3.750	1.044–13.472
Headache	0.618	0.127–2.994	0.550
Dizziness/vertigo	0.738	0.189–2.889	0.663
Fever	1.011	0.301–3.392	0.986
Vomiting	0.722	0.259–2.012	0.534
Cough	2.887	1.072–7.778
Abnormal vision	1.810	0.283–11.579	0.866
Abnormal hearing	–	–	1.000
Disturbance of consciousness	–	–	0.999
Altered mental status	0.853	0.176–4.135	0.844
Weakness	1.617	0.597–4.384	0.345
CD4/CD8	0.112	0.001–9.942	0.338
CD4 >100 count/mm	0.662	0.145–3.018	0.594
HIV viral load	1.035	0.594–1.802	0.904
Amphotericin B	4.038	0.754–21.643	0.103
Fluconazole	1.619	0.334–7.847	0.550
5-fluorocytosine	2.500	0.426–14.657	0.310
Itraconazole	2.615	0.597–11.455	0.202
Voriconazole	1.447	0.431–4.856	0.550
Drug combination	1.056	0.382–2.917	0.916
Use of recommended chemotherapy regimens	0.616	0.232–1.633	0.330
Hospital stay	0.928	0.888–0.970
Fluconazole treatment after discharge	1.172	0.242–5.677	0.844
Length of medication continuation after discharge	0.970	0.949–0.992
ART treatment	1.094	0.267–4.476	0.901
ART – antiretroviral therapy; CI – confidence interval; OR – odds ratio.